TY - JOUR
T1 - Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man
T2 - Lack of Correlation with β Cell Function
AU - Ruetten, Hartmut
AU - Gebauer, Mathias
AU - Raymond, Ralph H.
AU - Calle, Roberto A.
AU - Cobelli, Claudio
AU - Ghosh, Atalanta
AU - Robertson, R. Paul
AU - Shankar, Sudha S.
AU - Staten, Myrlene A.
AU - Stefanovski, Darko
AU - Vella, Adrian
AU - Wright, Kathryn
AU - Fryburg, David A.
N1 - Funding Information:
The methodological study described in this report was designed and implemented under the auspices of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium. The Biomarkers Consortium is a public private partnership that develops and validates biological markers, which speed up the development of therapies for the detection, prevention, diagnosis, and treatment of disease, and are ultimately aimed at improving patient care. For this study, the Consortium brought together diabetes experts from leading academic institutions, the Food and Drug Administration, The National Institutes of Health, the nonprofit sector, and the pharmaceutical industry to develop the project. The results of the partnership, discussed here, are important because they address a critical unmet medical need, and involve key stakeholders in the diabetes treatment field. FNIH has acted as a neutral convener for the partners and provided the project management expertise needed for the execution of the overall project. In the future, this type of partnership can be used as a model for establishing common standards for testing in other therapeutic areas as well. Under the auspices of the FNIH, this project was jointly funded by the NIH (NIDDK) and FDA, and the following, participating pharmaceutical companies: Amylin (now AstraZeneca), Janssen, Eli Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, and Takeda. An in-kind donation of P800 tubes was made by Becton Dickinson (D. Craft). Additional support was also received from ADA and JDRF. The authors also thank the staff and leadership of the FNIH for their continuous support in planning, executing, and managing these studies and the overall project.
Publisher Copyright:
© Copyright 2018, Mary Ann Liebert, Inc., publishers 2018.
PY - 2018/10
Y1 - 2018/10
N2 - Background: The aims of this study were to 1. define the responses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and peptide YY (PYY) to an oral meal and to intravenous L-arginine; and 2. examine correlation of enteroendocrine hormones with insulin secretion. We hypothesized a relationship between circulating incretin concentrations and insulin secretion. Methods: Subjects with normal glucose tolerance (NGT, n = 23), prediabetes (PDM, n = 17), or with type 2 diabetes (T2DM, n = 22) were studied twice, following a mixed test meal (470 kCal) (mixed meal tolerance test [MMTT]) or intravenous L-arginine (arginine maximal stimulation test [AST], 5 g). GLP-1 (total and active), PYY, GIP, glucagon, and β cell function were measured before and following each stimulus. Results: Baseline enteroendocrine hormones differed across the glucose tolerance (GT) spectrum, T2DM generally >NGT and PDM. In response to MMTT, total and active GLP-1, GIP, glucagon, and PYY increased in all populations. The incremental area-under-the-curve (0-120 min) of analytes like total GLP-1 were often higher in T2DM compared with NGT and PDM (35-51%; P < 0.05). At baseline glucose, L-arginine increased total and active GLP-1 and glucagon concentrations in all GT populations (all P < 0.05). As expected, the MMTT and AST provoked differential glucose, insulin, and C-peptide responses across GT populations. Baseline or stimulated enteroendocrine hormone concentrations did not consistently correlate with either measure of β cell function. Conclusions/interpretation: Both MMTT and AST resulted in insulin and enteroendocrine hormone responses across GT populations without consistent correlation between release of incretins and insulin, which is in line with other published research. If a defect is in the enteroendocrine/β cell axis, it is probably reduced response to rather than diminished secretion of enteroendocrine hormones.
AB - Background: The aims of this study were to 1. define the responses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and peptide YY (PYY) to an oral meal and to intravenous L-arginine; and 2. examine correlation of enteroendocrine hormones with insulin secretion. We hypothesized a relationship between circulating incretin concentrations and insulin secretion. Methods: Subjects with normal glucose tolerance (NGT, n = 23), prediabetes (PDM, n = 17), or with type 2 diabetes (T2DM, n = 22) were studied twice, following a mixed test meal (470 kCal) (mixed meal tolerance test [MMTT]) or intravenous L-arginine (arginine maximal stimulation test [AST], 5 g). GLP-1 (total and active), PYY, GIP, glucagon, and β cell function were measured before and following each stimulus. Results: Baseline enteroendocrine hormones differed across the glucose tolerance (GT) spectrum, T2DM generally >NGT and PDM. In response to MMTT, total and active GLP-1, GIP, glucagon, and PYY increased in all populations. The incremental area-under-the-curve (0-120 min) of analytes like total GLP-1 were often higher in T2DM compared with NGT and PDM (35-51%; P < 0.05). At baseline glucose, L-arginine increased total and active GLP-1 and glucagon concentrations in all GT populations (all P < 0.05). As expected, the MMTT and AST provoked differential glucose, insulin, and C-peptide responses across GT populations. Baseline or stimulated enteroendocrine hormone concentrations did not consistently correlate with either measure of β cell function. Conclusions/interpretation: Both MMTT and AST resulted in insulin and enteroendocrine hormone responses across GT populations without consistent correlation between release of incretins and insulin, which is in line with other published research. If a defect is in the enteroendocrine/β cell axis, it is probably reduced response to rather than diminished secretion of enteroendocrine hormones.
KW - GLP-1
KW - arginine
KW - incretin
KW - insulin secretion
KW - meal tolerance test
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85054388303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054388303&partnerID=8YFLogxK
U2 - 10.1089/met.2018.0022
DO - 10.1089/met.2018.0022
M3 - Article
C2 - 30117761
AN - SCOPUS:85054388303
SN - 1540-4196
VL - 16
SP - 406
EP - 415
JO - Metabolic Syndrome and Related Disorders
JF - Metabolic Syndrome and Related Disorders
IS - 8
ER -